The International Diabetes Closed Loop (iDCL) Trial: Protocol 1



Status:Recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:14 - Any
Updated:11/2/2017
Start Date:October 27, 2017
End Date:June 1, 2018
Contact:Stacey M. Anderson, MD
Email:sg4c@virginia.edu
Phone:434-982-0945

Use our guide to learn which trials are right for you!

Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes

The objective of the study is to assess the efficacy and safety of home use of a
Control-to-Range (CTR) closed-loop (CL) system.

The protocol is a 3-month parallel group multi-center randomized trial designed to compare
Control-to-Range (CTR) closed-loop (CL) with sensor augmented pump therapy (SAP).
Approximately 126 subjects will be entered into the randomized trial at approximately seven
clinical sites in the United States, such that at least 110 subjects complete the randomized
trial. A maximum of 200 subjects may be enrolled in the study in order to achieve the goal of
randomizing 126 subjects.

In order to have a broad range of glycemic control among the subjects, a study goal will be
to have a minimum of 50 subjects with HbA1c ≥ 7.5% and 50 with HbA1c < 7.5%.

Inclusion Criteria:

1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
one year and using insulin for at least 1 year

2. Use of an insulin pump for at least 6 months

3. Age ≥14 years old

4. HbA1c level <10.5% at screening

5. For females, not currently known to be pregnant

6. Willingness not to add glucose-lowering agents (such as Pramlintide, Metformin, GLP-1
analogs, SGLT2 inhibitors) during the study

7. Willingness, if not assigned to the closed-loop group, to avoid use of any closed-loop
control system for the duration of the clinical trial

8. Willingness to suspend use of any personal CGM for the duration of the clinical trial
once the unblinded study CGM is in use

9. Willingness to establish network connectivity on at least a weekly basis either via
local Wifi network or via a study-provided cellular service

10. Currently using no insulins other than one of the following rapid-acting insulins at
the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin
glulisine (Apidra)

11. Investigator has confidence that the subject can successfully operate all study
devices and is capable of adhering to the protocol

12. For subjects less than 18 years old, living with one or more parent/legal guardian
(referred to subsequently as diabetes care partner) committed to participating in
study training for emergency procedures for severe hypoglycemia and able to contact
the subject in case of an emergency

Exclusion Criteria:

1. Medical need for chronic acetaminophen

2. Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs,
SGLT2 inhibitors) in the 3 months prior to enrollment

3. Hemophilia or any other bleeding disorder

4. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk including any contraindication to the use of any of the
study devices per FDA labeling

5. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study

6. Use of a closed-loop system within the last month prior to enrollment

7. Employed by, or having immediate family members employed by TypeZero Technologies, LLC
We found this trial at
7
sites
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Bruce Buckingham, MD
Phone: 650-723-5791
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: R. Paul Wadwa, MD
Phone: 303-724-2323
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Boston, Massachusetts 00221
Principal Investigator: Francis Doyle, PhD
Phone: 617-732-2603
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlottesville, Virginia 22903
Phone: 434-982-0945
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Principal Investigator: Carol Levy, MD, CDE
Phone: 212-241-9089
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Yogish Kudva, MBBS, MD
Phone: 507-255-5916
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Santa Barbara, California 93105
Principal Investigator: Jordan Pinsker, MD
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials